electroCore (ECOR) announced that electroCore has received a new Federal Supply Schedule, FSS, contract, with an effective date of June 15, 2025 and running through June 14, 2030. “Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs FSS Service, demonstrating that gammaCore continues to be a cost effective therapeutic benefiting our veterans,” commented Dan Goldberger, Chief Executive Officer of electroCore. “VA Hospital revenue accelerated in February and March, after modest slowing in January 2025, reflecting continued demand for this drug-free method for addressing migraine headaches.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECOR:
- Electrocore’s Promising Growth and Strategic Positioning Earns Buy Rating from Analyst Vendetti
- ElectroCore’s Earnings Call: Robust Growth Amid Challenges
- electroCore price target lowered to $26 from $28 at Ladenburg
- ElectroCore Reports Strong 2024 Financial Growth
- ECOR Earnings Report this Week: Is It a Buy, Ahead of Earnings?